CONGRESS MATERIALS

Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Petrylak DP, Azad AA, Szmulewitz RZ, Iguchi T, Shore ND, Holzbeierlein J, Alekseev B, El-Chaar NN, Rosbrook B, Ma J, Zohren F, Haas GP, Stenzl A, Armstrong AJ September 9, 2022 ESMO 2022 Prostate Cancer

Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer Who Received Prior Androgen Deprivation Therapy and Reached Low Prostate-Specific Antigen Levels Treated Further With Enzalutamide: Post Hoc Analyses of ARCHES

View Presentation View Abstract Plain Language Summary
Poster
Gupta S, Hong A, El-Chaar NN, Young C, Ramaswamy K, Xie B, Bunner SH, Diessner BJ, Swami U September 9, 2022 ESMO 2022 Prostate Cancer

Real-World First-Line Treatment Patterns in Patients With High-Risk Nonmetastatic Castration-Resistant Prostate Cancer

View Presentation View Abstract Plain Language Summary
Poster
Ross AE, Iwata KK, Elsouda D, Hairston J, Russell D, Davicioni E, Proudfoot JA, Shore ND, Cooperberg MR, Schaeffer EM September 9, 2022 ESMO 2022 Prostate Cancer

Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance

View Presentation View Abstract Plain Language Summary
Poster
George DJ, Sandin R, Agarwal N, Tagawa ST, Klaassen Z, Bitting RL, Ramaswamy K, Emir B, Bland C, Hong A, Shi L, Yang H, Gao W, Song W, Freedland SJ September 9, 2022 ESMO 2022 Prostate Cancer

Treatment Patterns and Overall Survival (OS) in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) From 2010 to 2019

View Presentation View Abstract Plain Language Summary
Oral Presentation
Powles T, Sridhar SS, Bellmunt J, Sternberg CN, Grivas P, Hunter E, Dezfouli M, Salter M, Powel R, Ding A, Green J, Akoulitchev A, Amezquita R, Ching K, Pu J, Deng S, di Pietro A, Davis CB September 10, 2022 ESMO 2022 Urothelial Cancer

Genomic Biomarkers in Peripheral Blood (PB) From Patients (Pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

View Presentation
Poster
Hu X, Broughton E, Li W, Sun T, Shen K, Huang C-S, Sriuranpong V, Ngan KCR, Chia YH, Bhattacharyya H, Zhao H, Shen J, Xu B September 10, 2022 ESMO 2022 Breast Cancer

Patient-Reported Quality of Life in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole: Results From PALOMA-4

View Presentation View Abstract Plain Language Summary
Poster
Tripathy D, Rocque GB, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi M, Anderson D, Gauthier E, Zhang Z, Montelongo MZ, Wang Y September 10, 2022 ESMO 2022 Breast Cancer

Real-World Clinical Outcomes of Palbociclib Plus Endocrine Therapy in Hormone Receptor–Positive Advanced Breast Cancer: Results From the POLARIS Trial

View Presentation View Abstract Plain Language Summary
Poster
Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D September 10, 2022 ESMO 2022 Breast Cancer

Real-World Quality of Life in Patients With HR+/HER2– Advanced Breast Cancer Treated With Palbociclib: Final Clinical Outcome Assessment Analysis From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Schweizer MT, Penkov K, Tolcher A, Choudhury AD, Doronin V, Aljumaily RM, Calvo E, Frank RC, Hamm J, Moreno V, Vorobyev V, Billotte S, Bowler T, Chen J, Lin T, Liu L, Maity AK, Sharma S, Johnson M September 11, 2022 ESMO 2022 Other/Multi-Tumor

Phase I Trial of PF-06821497, a Potent and Selective Inhibitor of Enhancer of Zeste Homolog 2, in Follicular Lymphoma, Small-Cell Lung Cancer, and Castration-Resistant Prostate Cancer

View Presentation View Abstract Plain Language Summary
Poster
de Bono JS, Castro E, Laird AD, Fizazi K, Dorff T, Zhao S, van Oort IM, Gasparro D, Calabro F, Pignata S, Geczi L, Barthelemy P, Kilari D, Hopkins JF, Chen H-C, Healy CG, Chelliserry J, Scagliotti GV, Mehra N September 11, 2022 ESMO 2022 Prostate Cancer

TALAPRO-1: Talazoparib Monotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) With DNA Damage Response Alterations (DDRm)—Exploration of Tumor Genetics Associated With Prolonged Benefit

View Presentation View Abstract Plain Language Summary